AviadoBio Reclaims Full Rights to FTD Gene Therapy and Pushes Into Fourth Dose Cohort
AviadoBio regained full rights to its FTD gene therapy, secured disease-foundation funding, and initiated the fourth dose cohort — all in the same announcement.
Jeff Martin
Pelthos Takes the NaV1.7 Pain Target to Your Eyes With First Patient Dosed
NaV1.7 has been the white whale of pain drug development. Pelthos just dosed the first patient with a NaV1.7 inhibitor — but instead of systemic pain, they're targeting your eyeballs.
Ernexa Therapeutics Heads Toward IND With Engineered Stem Cells That Turn Cold Tumors Hot
Ernexa's ERNA-101 uses engineered stem cells to make cold tumors respond to immunotherapy — with complete tumor regression in preclinical models and an IND filing planned for Q3.
IO Biotech Goes From Breakthrough Designation to Bankruptcy
IO Biotech had a Breakthrough Therapy Designation, a Phase 3 with Merck, and Fast Company recognition. Then the FDA said no — and the company ceased to exist.
Trethera Takes Its Cancer Drug Into ALS With Mass General Collaboration
An oncology drug pivots into neurodegeneration — Trethera's TRE-515 enters expanded access in ALS patients at Massachusetts General Hospital.
Adcytherix Doses First Patient Just 21 Months After Incorporation
From founding to first patient in under two years — Adcytherix just entered the clinic with ADCX-020 after raising €135M. Its founders previously built the ADC company Lilly acquired.
Eli Lilly Buys Centessa for $6.3 Billion to Own the Orexin Franchise
Lilly didn't just buy a drug — they bought an entire orexin franchise. The $6.3B Centessa deal includes three OX2R agonists across clinical and preclinical stages.
TippingPoint Biosciences Raises $4.5M Seed to Target Pediatric Brain Cancer
TippingPoint just closed an oversubscribed $4.5M seed to go after DIPG — the deadliest childhood brain tumor — with a first-in-class epigenetic approach.
AI In Dermatology? Yeah, That’s A Thing Now. Thanks To Enveda Biosciences.
Enveda's ENV-294 hit 85% EASI reduction and 100% EASI-50 in Phase 1b for atopic dermatitis — and it's oral, first-in-class, and derived from plants.
Alltrna Sends the First tRNA Therapeutic Into Human Testing
Alltrna's AP003 just became the first tRNA-based drug to enter clinical trials — a milestone for an entirely new modality.